No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Gene Therapy Developers Rise on Comments From FDA's Makary
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $60
We're Not Very Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Rate
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Needham Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $60
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock